孕产妇对产前皮质糖类药物的血糖反应:一个范围审查
Annabel S Jones1, I-Lynn Lee1, Devaang Kevat2
1Department of Endocrinology and Diabetes, Western Health, St Albans, Victoria, Australia; Department of Medicine, University of Melbourne, St Albans, Victoria, Australia.
Journal of gynecology obstetrics and human reproduction
|September 11, 2025
概括
在没有糖尿病的妇女中,产前葡萄糖皮质类药物会导致显著的母性高血糖症,影响54-95%的病例. 需要进一步的研究来了解其对新生儿低血糖症的影响,并指导临床管理.
科学领域:
- 产科和妇科 产科和妇科
- 新生儿医学 新生儿医学
- 内分泌学 在内分泌学.
背景情况:
- 已知产前葡萄糖皮质类药物会在糖尿病妊娠中引起过渡性高血糖症.
- 在非糖尿病妇女和他们的新生儿中,产前葡萄糖皮质激素的血糖效应尚不清楚.
研究的目的:
- 在没有糖尿病的妇女中,研究产前葡萄糖皮质激素对胎儿肺部成熟的孕产妇血糖影响.
- 探索母亲高血糖症和新生儿低血糖症之间的关联.
主要方法:
- 在Ovid Medline和Embase进行了系统的文献搜索.
- 包括的研究报告了接受产前葡萄糖皮质类药物的非糖尿病妇女的血糖结果.
- 关键结局是母亲的血糖模式和新生儿低血糖患病率.
主要成果:
- 14项研究 (12个队列,2个RCT) 符合纳入标准.
- 在服用贝他美或德克萨米后,54-95%的非糖尿病女性报告了孕产妇高血糖症.
- 关于高血糖管理及其对母亲/新生儿结局的影响的数据有限.
结论:
- 在非糖尿病女性中,产前葡萄糖皮质类药物后,孕产妇高血糖非常普遍.
- 这种高血糖和新生儿低血糖等不良结果之间的联系需要进一步调查.
- 大规模的多中心试验是必要的,以建立监测和管理的临床指南.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
4.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.4K
Pathophysiology of Diabetes
3.2K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.2K
Hypoglycemia and Glucagon
839
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
839
Oral Hypoglycemic Agents: Biguanides and Glitazones
588
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
588
Overview of Carbohydrate Metabolism
3.3K
Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
3.3K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
526
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
526


